ART26.12, a novel fatty acid‐binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models

Documenti analoghi

• Evaluating FABP5 as a Therapeutic Target for Pain Management
  di: William Warren, et al.
  Pubblicazione: (2026)
• Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine
  di: Jeanne Rossignol, et al.
  Pubblicazione: (2024)
• Factors associated with patient no‐show rates in an academic pain management practice
  di: Aaron Burshtein, et al.
  Pubblicazione: (2025)
• B1.7 Precision Phytotherapy Blueprint: A Multi-Molecular Botanical Alternative for Opioid-Sparing Pain Management
  di: Landry, Marie Seshat
  Pubblicazione: (2025)
• Painful stimulation increases functional connectivity between supplementary motor area and thalamus in patients with small fibre neuropathy
  di: Sebastian Scheliga, et al.
  Pubblicazione: (2024)